Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a female seeking advice on using bicalutamide for female pattern hair loss (FPHL) and considering switching from pumpkin seed oil pills to a stronger treatment. She is looking for dosage information to discuss with her dermatologist.

Breezula results are awaited, but no updates have been posted. Users are uncertain about its promise.

BionicBell discussed using Bimatoprost, a medication typically for eyelash growth, for hair loss and mentioned a compounding pharmacy that can mix it with other ingredients like minoxidil and finasteride. They are seeking advice on using topical finasteride for female pattern baldness and are considering a custom foam combination to maximize hair growth results.

The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

A user was prescribed Alpicort E, which contains Estradiol Benzoate, Prednisone, and Salicylic Acid, for hair loss and is seeking others' experiences due to concerns about potential side effects.

A user noticed increased hair loss after taking B12 supplements for two months, with B12 levels rising to 1500. They are seeking help as other tests show normal levels of minerals and vitamins.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

The conversation is about someone wanting to import RU58841 or CB-03-01 from China for hair loss treatment but being concerned about receiving counterfeit products. Specific treatments mentioned are RU58841 and CB-03-01.

Breezula's development has stalled, leaving users disappointed. The conversation includes skepticism about its approval and effectiveness.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

Exosomes, cetirizine, melatonin, latanoprost, and caffeine are discussed as potential hair loss treatments. There is skepticism about the effectiveness of exosomes, especially in topical form, but some users report positive results.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

Breezula passed a clinical trial in August and there are questions about its availability in 2021 and potential delays due to Covid. No specific treatments were discussed.

Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

User found Annurmets, an Italian supplement with apple extract for hair loss treatment. Many reported incredible results using Procyanidin B2 from apple extract.

People are discussing Breezula, a hair loss treatment, with mixed opinions on its value for the cost. Some are interested in it, while others think it's not worth the money.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

CB-03-01 (Breezula) powder for hair loss. Users discuss its availability and seek feedback on its effectiveness.

Men discussing hair loss treatments, including bicalutamide, cyproterone acetate, dutasteride, minoxidil, and RU58841. They share experiences and concerns about side effects like infertility, liver health, and feminization.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

User asks about Annurmets Hair product, high in Procyanidin B2 for hair regrowth. Product is expensive and ordered from Italy.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.